阿司匹林与低分子量肝素血栓预防对用药满意度和自付费用的影响:一项随机临床试验的二次分析
阿司匹林组用药满意度更高(OR 2.59),发生任何自付费用的 odds 更高(OR 1.51),但自付费用≥25美元的 odds 更低(OR 0.15)。
要点
- 阿司匹林组用药满意度高于低分子量肝素组,OR 2.59(95%CI 2.39-2.80,p<0.001)。
- 阿司匹林组发生任何自付费用的 odds 为低分子量肝素组的1.51倍(95%CI 1.37-1.66,p<0.001)。
- 阿司匹林组自付费用≥25美元的 odds 更低,OR 0.15(95%CI 0.12-0.18,p<0.001)。
核心结论
- 骨科创伤后使用阿司匹林大幅改善患者对血栓预防药物的满意度。
- 阿司匹林增加发生任何自付费用的 odds,但降低自付费用≥25美元的 odds,可能改善血栓预防的健康公平性。
研究设计与样本
- 研究为PREVENT CLOT试验的二次分析,在美国和加拿大21个创伤中心开展。
- 纳入接受手术治疗的四肢骨折或骨盆/髋臼骨折成人患者,随机接受依诺肝素30mg每日两次或阿司匹林81mg每日两次进行血栓预防。
- 血栓预防持续时间(包括出院后处方)基于医院方案。
- 试验纳入12211例患者(平均年龄45±18岁,62%男性),其中9725例完成用药满意度问题,6723例报告自付费用。
主要发现
- 阿司匹林组获得更高满意度的 odds 为低分子量肝素组的2.6倍(OR 2.59;95%CI 2.39-2.80;p<0.001)。
- 阿司匹林组发生任何自付费用的 odds 较低分子量肝素组高51%(OR 1.51;95%CI 1.37-1.66;p<0.001)。
- 阿司匹林组自付费用至少25美元的 odds 大幅低于低分子量肝素组(OR 0.15;95%CI 0.12-0.18;p<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines recommend low-molecular-weight heparin for thromboprophylaxis after orthopaedic trauma. However, recent evidence suggests that aspirin is similar in efficacy and safety. To understand patients' experiences with these medications, we compared patients' satisfaction and out-of-pocket costs after thromboprophylaxis with aspirin versus low-molecular-weight heparin. METHODS: This study was a secondary analysis of the PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT) trial, conducted at 21 trauma centers in the U.S. and Canada. We included adult patients with an operatively treated extremity fracture or a pelvic or acetabular fracture. Patients were randomly assigned to receive 30 mg of low-molecular-weight heparin (enoxaparin) twice daily or 81 mg of aspirin twice daily for thromboprophylaxis. The duration of the thromboprophylaxis, including post-discharge prescription, was based on hospital protocols. The study outcomes included patient satisfaction with and out-of-pocket costs for their thromboprophylactic medication measured on ordinal scales. RESULTS: The trial enrolled 12,211 patients (mean age and standard deviation [SD], 45 ± 18 years; 62% male), 9725 of whom completed the question regarding their satisfaction with the medication and 6723 of whom reported their out-of-pocket costs. The odds of greater satisfaction were 2.6 times higher for patients assigned to aspirin than those assigned to low-molecular-weight heparin (odds ratio [OR]: 2.59; 95% confidence interval [CI]: 2.39 to 2.80; p < 0.001). Overall, the odds of incurring any out-of-pocket costs for thromboprophylaxis medication were 51% higher for patients assigned to aspirin compared with low-molecular-weight heparin (OR: 1.51; 95% CI: 1.37 to 1.66; p < 0.001). However, patients assigned to aspirin had substantially lower odds of out-of-pocket costs of at least $25 (OR: 0.15; 95% CI: 0.12 to 0.18; p < 0.001). CONCLUSIONS: Use of aspirin substantially improved patients' satisfaction with their medication after orthopaedic trauma. While aspirin use increased the odds of incurring any out-of-pocket costs, it protected against costs of ≥$25, potentially improving health equity for thromboprophylaxis. LEVEL OF EVIDENCE: Therapeutic Level II . See Instructions for Authors for a complete description of levels of evidence.
引用
- O'Hara NN, Frey KP, Stein DM, et al. Effect of Aspirin Versus Low-Molecular-Weight Heparin Thromboprophylaxis on Medication Satisfaction and Out-of-Pocket Costs: A Secondary Analysis of a Randomized Clinical Trial. J Bone Joint Surg Am. 2024. PMID: 38381842. doi:10.2106/JBJS.23.00824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。